Brief: Vigil Neuroscience Announces Interim Results From Phase 1 Clinical Trial Evaluating Vgl101 In Healthy Volunteers

Vigil Neuroscience

02/11/2022 11:22

Nov 2 (Reuters) - Vigil Neuroscience Inc  VIGL.O :
    * VIGIL NEUROSCIENCE ANNOUNCES INTERIM TOPLINE RESULTS FROM
ITS
ONGOING PHASE 1 CLINICAL TRIAL EVALUATING VGL101 IN HEALTHY
VOLUNTEERS SUPPORTING PHASE 2 INITIATION IN ALSP
    * VIGIL NEUROSCIENCE - VGL101 DEMONSTRATED FAVORABLE SAFETY,
TOLERABILITY AND PK PROFILES IN SINGLE ASCENDING DOSE AND
MULTIPLE ASCENDING DOSE COHORTS
    * VIGIL NEUROSCIENCE - VGL101 ACHIEVED DOSE DEPENDENT,
ROBUST AND
DURABLE DECREASES IN CSF STREM2 DEMONSTRATING PROOF OF TARGET
ENGAGEMENT
    * VIGIL NEUROSCIENCE INC - ON TRACK TO INITIATE PHASE 2
TRIAL WITH
A 20 MG/KG DOSE OF VGL101 IN ALSP PATIENTS THIS QUARTER
    * VIGIL NEUROSCIENCE- ADVERSE EVENTS MILD IN SEVERITY WITH
EXCEPTION OF ONE MODERATE AE OF DIZZINESS, AES RESOLVED WITHOUT
INTERVENTION IN VGL101 STUDY

Source text for Eikon:  ID:nGNXbT9Kl3 
Further company coverage:  VIGL.O 
 ((Reuters.Briefs@thomsonreuters.com;))